Navigation Links
Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Date:12/15/2009

NEW HAVEN, Conn., Dec. 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

Under the science plan for the collaboration, Dr. David Hooper of MGH will evaluate Rib-X's novel fluoroquinolone, delafloxacin, in an established animal model to determine resistance development and to validate the activity and mechanism of action of delafloxacin against microorganisms such as methicillin-resistant Staphylococcus aureus (MRSA).

"Treating infections that are resistant to the antibiotics currently available to us has become increasingly challenging," Dr. Hooper said. "We are interested to learn more about the unusual properties of this specific drug relative to other members of its class and its potential effect on controlling difficult and dangerous infections."

Delafloxacin, which is ready to enter Phase 3 clinical trials, is a novel, broad-spectrum, next-generation fluoroquinolone, that has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are quinolone-resistant.

"The opportunity to work with Dr. David Hooper on the in vivo mechanism of action of delafloxacin is a very important extension of the research we have done here at Rib-X," said Susan Froshauer, Ph.D., Rib-X's President and CEO. "Dr. Hooper is a well-known expert on fluoroquinolones and this collaboration will demonstrate the potential for delafloxacin to take its place in the arsenal of drugs for battling recalcitrant quinolone-resistant infections."

Rib-X previously announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSS
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
2. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
3. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
7. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
8. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
9. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
10. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
11. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Pa. , July 23, 2014 /PRNewswire/ ... today announced successful results from its randomized, ... in women with biopsy-proven cervical intraepithelial neoplasia ... types 16 or 18. Treatment with VGX-3100, ... of CIN2/3 to CIN1 or no disease, ...
(Date:7/23/2014)... WASHINGTON , July 23, 2014  Nearly 8,000 ... for Cardinal Health,s annual Retail Business Conference (RBC), ... & Convention Center. This year,s event encourages pharmacists to ... in their communities and for their future. ... pharmacy owners to network with their peers and learn ...
(Date:7/23/2014)... July 23, 2014  Mevesi Inc. would like ... This integration provides pharmacies with the ability to ... prospective patients. Mevesi,s solutions provide ... data to define target marketing campaigns. This coupled ... available within the Digital Marketing, Population Management, and ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
(Date:7/23/2014)... Steven Reinberg ... News) -- Many obese and overweight American children and ... weight is fine, U.S. health officials reported Wednesday. ... outcomes, such as high blood pressure, high cholesterol and ... at the U.S. Centers for Disease Control and Prevention,s ...
(Date:7/23/2014)... Home Care Assistance Calgary , North ... proud to announce the next installment in its renowned ... range of health and wellness-related fields. The upcoming webinar ... Nancy Kriseman, and will cover the most common causes ... becoming more self-aware. In particular, Nancy will discuss mindfulness ...
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
(Date:7/23/2014)... The American Telemedicine Association (ATA) ... annual meeting and tradeshow focused exclusively on telemedicine, ... over 5,000 attendees and more than 250 cutting-edge ... 2015, in Los Angeles. , ATA’s annual meeting ... from researchers, clinicians, hospital and university administrators, program ...
(Date:7/23/2014)... X syndrome ( FXS ) is a genetic disorder ... on the autistic spectrum, as well as cognitive deficits. ... impairment and the most common cause of autism. , ... have published a study that sheds light ... online today (July 23) in the Journal of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... released by the U.S. Centers for Disease Control and Prevention ... birth defects in the country.// ,"It helps to ... the import they have on families around the country," said ... March of Dimes Birth Defects Foundation in White Plains, New ...
... Southampton General Hospital says that by taking adequate amounts of ... their children.// In a study of 198 mothers, it was ... their kids had greater bone densities. ,"This is ... mother's vitamin D levels before," said lead researcher Professor Cyrus ...
... in the crown of physical exercisers. A new study in ... wound-healing process by as much as 25 percent//. ... will become infected. ,The results appear in a ... ,This is the first time such an enhancement associated ...
... The Journal of Science has published a research report ... mood and sleep, and also plays an important// role ... suffering from depressive illnesses, the best pharmacological treatments are ... p11, is closely related to serotonin transmission in the ...
... Zealand Veterinary Association is on war path against Australian euthanasia ... get deadly drugs//. ,Dr Nitschke told more than ... option for those wanting to die was to approach a ... Veterinary Association chief executive Murray Gibb said such advice was ...
... majority of Californian adults are of the opinion, that ... the State’s Public Schools//, according to a survey, by ... 75% of respondents opted for programs with information on ... 17% favored information on mere abstinence programs. At least ...
Cached Medicine News:Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 2Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 3Health News:Scientists Identify Gene Responsible For Depression 2Health News:Kiwi veterinarians angry Over Doctor's Advice 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... original Magstim design the new Magstim 200 ... of knowledge and expertise gathered in both ... an innovative design that will help further ... system of preferred choice. Ergonomic modular ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: